Table 1.

Comprehensive summary of published studies on montelukast and/or nasal corticosteroids for mild OSA.

Study	Design	Patients number (age)	PSG	Treatment	Dose	Duration	Control
Corticosteroids
Brouillette 2001	RCT	25 (1–10 y)	AHI > 1/h	Fluticasone	50 μg c/12 h,1 week; 50 μg/24 h, 5 weeks	6 weeks	Placebo
Yilmaz 2003	RCT	28 (12–18 y)	No PSG	Mometasone	200 μg	6 weeks	–
Criscuoli 2003	RCT	53 (3.8 ± 1.3 y)	No PSG	Beclomethasone	400 ug	2 weeks, 24 weeks	–
Cengel 2006	RCT	122(3–15 y)	No PSG	Mometasone	100 μg	6 weeks	–
Berlucchi 2007	RCT	60 (3–7 y)	No PSG	Mometasone	100 μg	40 weeks	–
Kheirandish-Gozal 2008	RCT, crossover	62 (6–12 y)	Mild OSA	Budesonide	32 μg × nostril	6 weeks, washout, 6 weeks	Placebo
Barghawa 2014	RCT	100 (2–12 y)	No PSG	Mometasone	200 μg	8 weeks	–
Barghawa 2014	RCT	60 (2–12 y)	No PSG	Mometasone	200 μg	8 weeks	–
Hassanzadel 2013	RCT	40 (4–12 y)	No PSG	Mometasone	400 μg	4 weeks	–
Rehman 2013	RCT	112 (3–8 y)	No PSG	Mometasone	NR	8 weeks	–
Montelukast
Goldbart 2005	RCT	24 (2–10 y)	AHI 1–8/h	Montelukast	4/5 mg	12 weeks	Placebo
Kheirandish-Gozal 2016	RCT	64 (2–14 y)	PSG-Mild OSA (AHÍ < 7/h)	Montelukast	4/5/10 mg	16 weeks	Placebo
Montelukast and corticosteroids
Kheirandish-Gozal 2014	Retrospective	752 (2–14 y)	PSG-Mild OSA (AHÍ<5/h)	Montelukast and corticosteroids	variable	12 weeks	–
Tuhaniouglu 2017	RCT	120 (4–10 y)		Mometasone Montelukast Both None	100 μg 4/5 mg	12 weeks	Corticosteroids

RCT: randomized controlled trial; OSA: obstructive sleep apnea; PSG: polysomnography.